Predictive Factors of Recurrent Bleeding in Mallory-Weiss Syndrome by �씠�룞湲� & �씠�룞湲�
대한소화기학회지 2005;46:447-454
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
접수: 2005년 8월 8일, 승인: 2005년 11월 23일
연락처: 김현수, 220-701, 강원도 원주시 일산동 162번지
연세대학교 원주의과대학 내과학교실 소화기내과
Tel: (033) 741-1229, Fax: (033) 741-1228
E-mail: hskim@wonju.yonsei.ac.kr 
Mallory-Weiss 증후군 환자에서 재출혈의 예측인자
연세대학교 원주의과대학 내과학교실, 의과대학 내과학교실*
김재우․김현수․변종원․원찬식․지명관․박용순․백순구․권상옥․이동기* 
Predictive Factors of Recurrent Bleeding in Mallory-Weiss Syndrome
Jae Woo Kim, M.D., Hyun Soo Kim, M.D., Jong Won Byun, M.D., Chan Sik Won, M.D., 
Myeong Gwan Jee, M.D., Yong Soon Park, M.D., Soon Koo Baik, M.D., 
Sang Ok Kwon, M.D., and Dong Ki Lee, M.D.*
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju; 
Department of Internal Medicine, Yonsei University College of Medicine*, Seoul, Korea
Background/Aims: Although the majority of patients with Mallory-Weiss syndrome (MWS) have a benign course, 
MWS patients with recurrent bleeding have an unfavorable outcome and require intensive care. Therefore, this 
study was carried out to identify the risk factors for recurrent bleeding in MWS patients. Methods: The medical 
records of patients with MWS between January 1999 and December 2003, were reviewed retrospectively. Demo-
graphics, initial clinical and laboratory parameters, and endoscopic findings of the patients with and without recur-
rent bleeding were compared and the potential risk factors predicting recurrent bleeding in MWS were evaluated. 
Results: A total of one hundred and fifty-nine patients (22 women, 137 men, mean age 48.1 years old) were 
enrolled in the study. Recurrent bleeding was observed in 17 patients (10.7%). Those patients with recurrent 
bleeding showed higher frequency for the presence of shock at initial manifestation, combined liver cirrhosis and 
endoscopic findings of active bleeding, lower hemoglobin level and platelet count, higher amount of transfusions 
and epinephrine-mixed fluid injections, and longer hospital stay than those patients without recurrent bleeding. 
Significant risk factors predicting the recurrent bleeding in MWS were the presence of shock at initial 
manifestation (OR 3.71, 95% CI 1.07-14.90) and the evidence of active bleeding on endoscopic examination (OR 
9.89, 95% CI 1.88-51.98) on multivariate analysis. Conclusions: Intensive care with close monitoring is required 
for the patients with shock on initial manifestation or with evidence of active bleeding on endoscopic 
examinations since these are independent risk factors predicting the recurrent bleeding in MWS patients. (Korean 
J Gastroenterol 2005;46:447-454)
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INTRODUCTION
  Mallory-Weiss syndrome (MWS), which manifests as 
lacerations in the region of the gastroesophageal junction that 
typically occur in gastric mucosa, is a common cause of upper 
gastrointestinal (GI) hemorrhage. MWS has been reported to be 
the cause of upper GI bleeding in approximately 3% to 15% of 
all cases. However, most patients require no intervention other 
than hemodynamic support.1,2 On the other hand, patients with 
severe or recurrent bleeding related to MWS must undergo 
intensive care even the majority of patients with MWS features 
a benign course and a lower rate of recurrent bleeding when 
compared to other causes of upper GI bleeding.3-5 
  Several studies of endoscopic hemostasis have reported that 
recurrent bleeding rates for upper GI bleeding in MWS patients 
is 8-15%.6,7 Moreover, MWS patients with recurrent bleeding 
have an unfavorable outcome and a worse prognosis than 
patients without recurrent bleeding. In patients with non-variceal 
bleeding other than MWS, there are well-recognized clinical 
and laboratory risk factors associated with patients at risk for 
complications, recurrent bleeding, and mortality.8-14 However, 
there are few reports on the factors predicting recurrent 
bleeding in MW tear.6,15 Therefore, the aims of this study were 
to compare the clinical and laboratory parameters, and endos-
copic findings of patients with or without recurrent bleeding, 
and to identify the risk factors associated with recurrent 
bleeding using multivariate logistic regression analysis.
PATIENTS AND METHODS
  1. Patients 
  Between January 1999 and December 2003, a total of 159 
patients presenting with a MW tear were enrolled and retro-
spectively analyzed. During the same period, 2,379 patients had 
been diagnosed as UGI bleeding, and therefore 6.7% were 
caused by MW tear. MW tears were defined as a mucosa 
laceration of the esophagus or stomach near the eso-
phagogastric junction on endoscopic inspection. The demo-
graphics of the patients, the presence of chronic disease such as 
Table 1. Patients Characteristics according to the Presence of Recurrent Bleeding
Parameters Recurrent bleeding (n=17) No recurrent bleeding (n=142)  p-value
Age (yrs, SD) 51.3±13.2 47.7±14.3 0.330
Sex (M, %)  17 (100) 120 (85) 0.080
ASA status (1/2/3) 9/8/0  92/44/6 0.324
Comorbid disease (yes, %) 9 (52)  56 (39) 0.284
Liver cirrhosis (yes, %) 7 (41)  26 (18) 0.028
PHx of peptic ulcer (yes, %) 0 (0)  21 (14) 0.089
Alcohol consumption (yes, %) 14 (82)  98 (69) 0.255
ASA, American society of anesthesiologists; SD, standard deviation; PHx, past history.
Table 2. Initial Clinical and Laboratory Findings according to the Presence of Recurrent Bleeding 
Parameters Recurrent bleeding (n=17) No recurrent bleeding (n=142) p-value
Hematemesis or melena (yes, %) 17 (100) 129 (90)   0.193
Shock status (yes, %) 10 (58) 26 (18) ＜0.001
  0.006Systolic BP (mmHg, SD)  94.0±18.3 108.0±19.6
＜0.001Diastolic BP (mmHg, SD)  55.4±15.4  68.5±13.6
 0.026Pulse rate (SD) 118.5±28.8 105.2±22.1
 0.043Hemoglobin (g/dL, SD)  9.8±3.2 11.2±2.6
 0.030Platelet count (103/mm3, SD) 159.2±70.2  215.2±102.2
 0.392PT (INR, SD)  1.3±0.6  1.1±0.8
 0.343PTT (sec, SD)  31.3±12.1 29.0±8.9
BP, blood pressure; SD, standard deviation; PT, prothrombin time; INR, international normalized ratio; PTT, partial 
thromboplastin time.
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liver cirrhosis, diabetes mellitus, and cardiovascular disease, and 
a prior history of alcohol consumption or peptic ulcer was 
recorded. The clinical parameters included general physical 
status, presenting symptoms of melena or hematemesis as well 
as the pulse rate and blood pressure at initial manifestation. 
General physical status was assessed according to the ASA 
five-categorial classification system.16 The following laboratory 
data from hospital database were also examined: hematocrit, 
platelet counts, and clotting parameters (prothrombin time, 
partial thromboplastin time, international normalized ratio 
[INR]). Shock was defined as a systolic pressure of ＜100 
mmHg and a pulse rate ＞100 beat per minute accompanied by 
pallor or cold sweating. These variables were evaluated as 
being potential risk factors for recurrent bleeding. Comparison 
of the potential risk factors were made between the patients 
with and without recurrent bleeding.
  2. Methods
  Endoscopy was performed by one of 3 endoscopists using a 
standard upper endoscope (GIF-XQ 230, 240, or 260, Olympus 
Optical Co., Ltd., Tokyo, Japan). According to the endoscopic 
findings, the number and location of MW tears, the length of 
the longest tear, the presence of a hiatal hernia, and the type of 
stigmata were recorded. The type of stigmata was classified as 
active or non-active bleeding based on initial endoscopic 
finding. Active bleeding during endoscopy was defined as 
arterial spurting or oozing, whereas non-active bleeding was 
defined as non-bleeding focal endoscopic stigmata (visible 
vessel, fresh adherent clot, and black clot) or clean-based tears. 
In addition, primary hemostasis was defined as an endos-
copically verified cessation of bleeding after the first endos-
copic session of the hemostatic procedure. Recurrent bleeding 
was defined as a recurrence of hematemesis, a bloody nasogas-
tric aspirate, or a decrease in the hemoglobin concentration of 
＞1.5 g/dL within 24 hours after successful primary hemostasis. 
Follow-up endoscopy was performed within 12 hours if 
recurrent bleeding was suspected. Permanent hemostasis was 
defined as an absence of recurrent bleeding during a 30-day 
period after the primary hemostasis. 
  3. Statistical analysis
  Study database management and all statistical analyses were 
performed using the SPSS software, version 12.0 for Windows 
(SPSS Inc, Chicago, IL). The student t-test was used to 
compare the mean values of the continuous variables, and 
chi-square test was used to analyze the categorical data. All 
results are expressed as a mean±SD unless otherwise stated. In 
addition, multiple logistic regression analysis for the risk factors 
of recurrent bleeding was carried out to determine the relative 
risks as odds ratio (OR) with 95% confidence intervals (CIs). 
For multivariate analysis of the continuous variables, the 
patients were categorized after normalizing them to the mean 
values. p value ＜0.05 was considered significant. The study 
was carried out in accordance with the Helsinki Declaration as 
revised in 1989.
RESULTS
  1. Characteristics of the patients
  Of 159 patients with MWS, 17 patients (10.7%) presented 
with recurrent bleeding. These patients were compared with 142 
patients who did not reveal recurrent bleeding. The demogra-
phics of the patient and initial general physical status were not 
associated with the risk of recurrent bleeding. In addition, there 
was no significant differences in the risk of recurrent bleeding 
for those patients with comorbid diseases including diabetes or 
cardiovascular disease. A prior history of peptic ulcer or 
alcohol abuse had no influence on the risk of recurrent 
bleeding. However, the proportion of patients with comorbid 
liver cirrhosis was higher (41% vs. 18%, p=0.028) in those 
patients with recurrent bleeding (Table 1). 
  2. Clinical and laboratory findings 
  No difference was found between the patients with or 
without recurrent bleeding with respect to the presenting 
symptoms of hematemesis or melena (Table 2). However, the 
initial manifestation of shock was more frequently observed 
(58% vs. 18%, p＜0.001) in those patients with recurrent 
bleeding. In addition, the systolic and diastolic blood pressures 
at initial presentation were lower in the patients with recurrent 
bleeding (p=0.006 and p＜0.001, respectively), and the initial 
pulse rate was higher (p=0.026). The laboratory findings 
showed that the hematocrit level and platelet counts were 
significantly lower (p=0.043 and p=0.03, respectively) in those 
patients with recurrent bleeding. However, the clotting 
parameters in both groups were similar.
  3. Endoscopic findings 
  We compared the initial endoscopic finding of the patients 
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with or without recurrent bleeding. The status of stigmata, and 
active bleeding such as spurting or active oozing from the MW 
tear were associated with recurrent bleeding. Active bleeding 
was endoscopically documented in 88% (15/17) of patients with 
recurrent bleeding as opposed to 38% (55/142) of patients 
without (p＜0.001). On the other hand, the number and location 
of the tear, the length of the tear, the presence of hiatal hernia, 
and waiting time for endoscopy were similar in both groups 
(Table 3).
  4. Clinical outcomes 
  We analyzed the clinical outcomes according to the presence 
of recurrent bleeding. Endoscopic hemostasis due to active 
bleeding and visible vessel on initial endoscopy was performed 
in 89 of the 159 patients. Of these, primary hemostasis was 
successfully achieved in 85/89 (95.5%) patients and was 
comparable in patients with or without recurrent bleeding (94% 
vs. 95%; p=0.579). The treatment modalities were significantly 
different between two groups (p=0.001). Endoscopic therapeutic 
intervention was required in all patients with recurrent bleeding, 
whereas half of the patients without recurrent bleeding did not 
require endoscopic hemostasis. In particular, 36% of patients 
with recurrent bleeding required more intensive endoscopic 
treatments requiring epinephrine injections and hemoclip to 
achieve the primary hemostasis. However, the rate of primary 
hemostasis was not significantly different between two groups 
treated by epinephrine injection alone and treated by both 
injection and hemoclip (p=0.878). Among patients treated with 
endoscopic injection therapy, alone larger volume of 
epinephrine injection was needed to control the bleeding (13.5 
mL vs. 6.0 mL; p＜0.001) in the patients with recurrent 
bleeding (13.5 mL vs. 6.0 mL; p＜0.001). In addition, larger 
amounts of transfusion was required (4.7 vs. 1.9; p= 0.024) in 
the patients with recurrent bleeding. Among 17 patients with 
recurrent bleeding, 16 (94%) patients achieved successful 
primary hemostasis while one patient underwent surgery as a 
Table 3. Endoscopic Findings according to the Presence of Recurrent Bleeding
Parameters Recurrent bleeding (n=17) No recurrent bleeding (n=142)  p-value
Number of tearing 
  ≤1 
  ≥2
 13 (76%) 
  4 (24%)
117 (82%) 
 25 (18%)
0.550
Location of tearing 
  Distal esophagus 
  Gastroesophageal junction 
  Cardia
 6 (35%)
11 (65%) 
0
71 (50%) 
58 (40%) 
13 (10%)
0.121
Length of tearing (cm) 
  ≤1.5 
  ＞1.5 
8 (47%) 
9 (53%)
91 (64%) 
51 (36%)
0.171
Hiatal hernia 
  No 
  Yes
17 (100%) 
0
134 (94%) 
 8 (6%)
0.315
Waiting time for EGD (hours, SD) 5.1±3.8 14.2±25.5 0.147
EGD finding 
  Active bleeding 
    Spurting 
    Oozing 
  Non-active bleeding 
    Visible vessel 
    Adherent clot 
    Black base 
    Clean base
 3 (18%) 
12 (70%) 
 2 (12%) 
0 
0 
0
 7 (5%) 
 48 (34%) 
 23 (16%) 
 20 (14%) 
13 (9%)
 31 (22%)
＜0.001
EGD, esophagogastroduodenoscopy; SD, standard deviation.
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result of unsuccessful endoscopic hemostasis. Despite permanent 
hemostasis, one patient in the recurrent bleeding group died 
from hepatorenal syndrome. In patients without recurrent 
bleeding, primary hemostasis was achieved in 69 out of 72 
(95%) patients which is similar to the recurrent bleeding group 
(p=0.579). Of these, one patient underwent surgery because of 
failed primary hemostasis and discharged with uneventful 
hospital course. Three patients died without further bleeding as 
a result of complications associated with liver cirrhosis; 
alcoholic ketoacidosis or hepatic failure. Therefore, permanent 
hemostasis was successfully achieved in 15 (88%) patients with 
recurrent bleeding. In contrast, permanent hemostasis was 
achieved in all patients without recurrent bleeding (p=0.001). 
The duration of the hospital stay was shorter (6.4 days vs. 8.5 
days; p=0.004) in patients without recurrent bleeding (Table 4). 
  
    5. Multivariate analysis of risk factors for recurrent 
bleeding 
  The results of multivariate analysis which includes the 
potential risk variables predicting recurrent bleeding, are sum-
marized (Table 5). Multivariate analysis identified the initial 
manifestation of shock (odds ratio [OR] 3.71; 95% confidence 
interval [CI] 1.07-14.90) and the initial endoscopic finding of 
active bleeding (OR 9.89; 95% CI 1.88-51.98) as factors 
associated with increased risk of recurrent bleeding. Comorbid 
liver cirrhosis was associated with marginal but non-significant 
increase in risk. Other potential risk variables including age (≥
50 years), alcohol consumption, hemoglobin level or platelet 
count, and the number or the location of MW tear were not 
significant in predicting the recurrent bleeding of MWS. 
Table 4. Clinical Outcomes according to the Presence of Recurrent Bleeding
Parameters Recurrent bleeding (n=17) No recurrent bleeding (n=142)  p-value
Treatment modalities 
  Epinephrine injection 
  Combination (injection+hemoclip) 
  Conservative care
Volume of epinephrine-mixed fluid
Amounts of transfusion (units, SD)
Primary endoscopic hemostasis (n=89)
Permanent hemostasis 
Surgical treatment 
Bleeding-related deaths 
Hospital stay (days, SD)
11 (64%) 
 6 (36%) 
0
13.5±8.1
4.7±4.5
16/17 (94%)
  15 (88%)
  1 (5%)
0
8.5±2.7
48 (34%) 
24 (17%) 
70 (49%)
6.0±7.7
1.9±2.6
69/72 (95%)
  142 (100%)
   1 (0.7%)
0
6.4±2.9
0.001
＜0.001
0.024
0.579
0.001
0.070
1.000
0.004
SD, standard deviation.
Table 5. Multivariate Analysis of Risk Factors for Recurrent Bleeding in Mallory-Weiss Syndrome
Parameters Odds ratio 95% CI p-value
Age (＜50 vs. ≥50 years) 1.85 0.57-6.04 0.310
Liver cirrhosis (yes vs. no) 2.74  0.75-10.04 0.129
Alcohol drinking (yes vs. no) 1.43 0.32-6.43 0.639
Shock (yes vs. no) 3.71  1.07-14.90 0.039
Hemoglobin (＜11 g/dL vs. ≥11 g/dL ) 1.66 0.47-5.81 0.430
Platelet counts (＜105/mm3 vs. ≥105/mm3) 0.47 0.11-2.04 0.312
EGD finding (active vs. non-active bleeding) 9.89  1.88-51.98 0.007
Number of tearing (＞1 vs. ≤1) 1.22 0.30-4.90 0.785
Length of tearing (＞1.5 cm vs. ≤1.5 cm) 1.03 0.30-3.56 0.964
CI, confidence interval; EGD, esophagogastroduodenoscopy.
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DISCUSSION
  MW tears are common source of non-variceal GI bleeding 
and generally have a benign course in more than 90% of 
cases.2,17 Although the recurrent bleeding rate in MWS is lower 
than that of other non-variceal hemorrhage, the prognosis of 
uncontrolled recurrent bleeding are worse than that of con-
trolled bleeding.6,18 In particular, recurrent bleeding in MWS 
might require additional blood transfusions, repeated hemostatic 
procedures, and surgery in cases of inadequate treatment.18,19 
Therefore, identifying the risk factors associated with recurrent 
bleeding will provide useful informations on risk stratification 
and eventually improve the patients' clinical outcomes through 
intensive care with close monitoring.
  With respect to the conditions associated with MWS, several 
studies have suggested that chronic alcohol abuse,20,21 the 
presence of hiatal hernia,20,22 and portal hypertension22 are asso-
ciated with MWS. However, the relationship between patient- 
associated variables and the risk of recurrent bleeding of MWS 
are unclear. In this study, the proportion of those with liver 
cirrhosis was significantly higher in the recurrent bleeding 
group. However, multivariate analysis revealed that this variable 
is only marginally associated with the risk of recurrent bleeding 
(OR 2.74, p=0.129). Moreover, the distribution of age, gender, 
the general physical status, the proportion of those with 
comorbid disease, and prior alcohol abuse were not significant 
risk factors. Therefore, the patients characteristics including 
comorbid diseases were not major determinants in recurrent 
bleeding of MWS. 
  In the aspect of clinical and laboratory parameters, initial 
manifestation of shock with lower blood pressure and higher 
pulse rate was more frequently observed in patients with 
recurrent bleeding. In addition, hemoglobin levels and platelet 
counts were significantly lower in these patients. Multivariate 
analysis revealed that the presence of shock at initial mani-
festation is a predictive risk factor of recurrent bleeding. 
Therefore, it is believed that initial clinical and laboratory 
findings are significantly related with the risk of recurrent 
bleeding, and special emphasis on these parameters is needed. 
In the present study, the parameters of coagulopathy were not 
found to be different. Discrepancy was noted between the 
frequency of liver cirrhosis in the univariate comparison and 
the predictors for recurrent bleeding in multivariate analysis. 
Univariate analysis showed higher frequency of combined liver 
cirrhosis in patients with recurrent bleeding. However, this 
relationship was broken after the adjustment by multivariate 
analysis. This suggests that severe or massive bleeding at initial 
manifestation is a significant predictor of recurrent bleeding in 
MWS rather than the presence of coagulopathy or liver 
cirrhosis. However, further study is needed to determine the 
relative contributions of these variables to clinical outcomes. 
  The frequency and prognostic significance of active bleeding 
or nonbleeding focal stigmata at initial endoscopy vary in 
MWS on account of the differences in the time interval 
between the onset of bleeding, symptoms and initial endos-
copy.6,15 In this study, most patients (88%) with recurrent 
bleeding showed active (spurting or oozing) bleeding at initial 
endoscopy, whereas only 38% of patients without recurrent 
bleeding showed active (spurting or oozing) bleeding (p＜
0.001). This relationship is supported by multivariate analysis, 
which found a risk of recurrent bleeding in MWS patients with 
an odds ratio of 9.89. However, the number, length and 
location of MW tearing, and the presence of a hiatal hernia did 
not have any significant effect. These results emphasize the 
need for endoscopists to take every effort to prevent recurrent 
bleeding in patients who presented with active bleeding at 
initial endoscopy.
  Mallory-Weiss patients with hemostatic treatment showed 
more severe hemorrhagic episodes and had higher risk of upper 
GI bleeding (higher heart rate, lower systolic pressure, lower 
hemoglobin values, and higher transfusion requirements) than 
those without.7 It also showed that endoscopic hemostatic 
procedures including combination treatments are performed 
more frequently in patients with recurrent bleeding. In addition, 
it has been reported that a low initial hemoglobin level is 
associated with recurrent bleeding.15 In addition, the volume of 
injected epinephrine-mixed fluid was larger in those patients 
with recurrent bleeding. Therefore, there appears to be a 
relationship between the need for endoscopic intervention upon 
admission and the increased risk of recurrent bleeding, an index 
of poor outcome. In this study, the requirement of transfusion 
and the length of hospital stay were higher and longer in 
patients with recurrent bleeding which reflects poor clinical 
outcomes. 
  In summary, these results show that several risk factors are 
positively associated with the risk of recurrent bleeding. Uni-
variate analysis revealed following significant risk factors: the 
presence of liver cirrhosis or shock, low hemoglobin levels and 
platelet counts, low blood pressure and a high pulse rate at 
admission as well as an endoscopic finding of active bleeding. 
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Multivariate analysis identified two independent factors which 
could predict the recurrent bleeding in MWS: shock at an 
initial presentation and active bleeding at an initial endoscopy. 
Therefore, careful consideration of these variables can provide 
optimal therapeutic strategy which would improve the clinical 
outcome in these patients. 
요      약
  목적: Mallory-Weiss 증후군 환자의 대다수는 양호한 임
상경과를 보이나 출혈이 재발하면 집중 치료가 필요할 뿐만 
아니라 예후가 나쁘다. 이번 연구는 재출혈 여부에 따른 환
자군의 특성을 비교하고 이에 관여하는 위험 인자들을 알아
보고자 하였다. 대상 및 방법: 1999년 1월부터 2003년 12월 
사이에 본원에서 Mallory-Weiss 증후군으로 진단 받은 환자
들을 후향 분석하였다. 재출혈 유무에 따른 환자 특성, 내원 
당시 임상 및 혈액학 변수, 그리고 내시경 소견을 비교하였
고 재출혈에 대한 관련 인자를 평가하였다. 재출혈은 토혈 
재발, 위관을 통한 출혈성 흡인물의 확인 또는 초기 지혈술 
후 24시간 내에 혈색소가 1.5 g/dL 이상 감소한 경우로 정의
하였다. 결과: 대상 환자는 총 159명(여자 22명, 남자 137명)
이었으며 평균 나이는 48세였다. 재출혈은 17명(10.7%)에서 
발생하였다. 재발군은 비재발군에 비하여 내원 당시 쇼크와 
간경변증 동반율이 높았으며 내시경 소견에서 활동성 출혈 
빈도가 높았고 내시경 지혈 시 에피네프린 함유 용액의 요
구량이 많았다. 또한 내원 당시 혈색소와 혈소판수가 낮았
으며 수혈 요구량과 입원 기간이 비재발군에 비해 증가하였
다. 다변량 분석 결과 Mallory-Weiss 병변의 재출혈을 예측
할 수 있는 위험 인자로는 초기 내원 시 쇼크 유무(비교위
험도 3.71, 95% CI 1.07-14.90)와 내시경으로 확인된 활동성 
출혈(비교위험도 9.89, 95% CI 1.88-51.98)이 의미 있는 인자
로 나타났다. 결론: 초기 내원 시 쇼크의 존재와 내시경에
서의 활동성 출혈은 Mallory-Weiss 환자에서 재출혈과 관련
된 독립적인 위험 요소가 되므로 이러한 소견이 있는 경우 
적극적인 감시와 집중 치료가 필요하리라 생각한다. 
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
색인단어: Mallory-Weiss 증후군, 일차 지혈, 재출혈
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